SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03686085

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Effects of Prophylactic Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women.

To investigate whether vaginal dinoprostone administered before intrauterine device (IUD) insertion reduces failed insertions, insertion-related complications and pain in nulliparous women.

NCT03686085 Intrauterine Device

2 Interventions

Name: Dinoprostone 3 mg

Description: 1 vaginal tablet of dinoprostone (3mg) (prostinĀ® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.

Type: Drug

dinoprostone arm

Name: placebo vaginal tablet

Description: 1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.

Type: Drug

placebo


Primary Outcomes

Description: easiness score of IUD insertion (easy\difficult-very difficult)

Measure: easiness score of IUD insertion

Time: 5 minutes

Secondary Outcomes

Description: the difference in the pain intensity scores between the study groups BY visual analog scale score then categorized to absent-mild-moderate-severe.

Measure: the difference in the pain intensity scores between the study groups

Time: 5 minutes

Purpose: Prevention

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 T380A

Effects of Prophylactic Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women.. Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women. --- T380A ---

Effects of Prophylactic Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women.. Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women. --- T380A --- --- T380A ---



HPO Nodes